BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
TScan Therapeutics is cutting approximately 75% of its workforce, pausing enrollment in its Phase 3 ALLOHA-2 trial of TSC-101, and refocusing on in vivo TCR T therapies for solid tumors targeting PRAME and MAGE-A4, per its release; TCRX closed down 42.8%.
Novartis signed an option and license agreement with Alteogen worth up to $3.2 billion for subcutaneous formulations of selected products using the ALT-B4 hyaluronidase platform; no upfront was disclosed, and the total includes royalties.
uniQure submitted a BLA seeking accelerated approval of AMT-130, the first license application for any Huntington's disease gene therapy, along with a UK filing, and requested priority review; QURE closed down 3.4%.
CMS Administrator Mehmet Oz says 600,000 seniors signed up for the Medicare GLP-1 bridge program in two months; the White House claims $216 million saved; Jefferies pegs the annualized run rate at $1.5 billion to $1.8 billion.
Teva's anti IL-15 antibody TEV-408 met its Phase 2a primary endpoint in celiac disease with no effect sizes published, per the company; TEVA closed up 3.6%.
Cellares cut 68 more roles after losing its largest customer, identified as Bristol Myers Squibb by Fierce Pharma, bringing announced cuts to 168, and the SEC and FDA signed a three year information sharing agreement aimed at insider trading.
⚡ Executive Takeaway
On Tuesday night we framed the halt as an open question: what is ex vivo autologous cell therapy worth outside oncology? Wednesday supplied the first three data points, and they all point the same way. A seller: TScan, which kept nothing ex vivo and hung a for sale sign on its autoimmune program. Infrastructure: Cellares, shrinking again after its anchor customer walked. And a buyer: Novartis, which watched a rapid manufacturing platform generate three deaths a day earlier and chose to put its next three billion dollars of headline value on the least cellular thing in biologics, an enzyme that turns IV drugs into shots.
None of that waited for a safety review to read out. That is the transferable lesson: when a safety event lands on a modality whose economics were already marginal, capital does not wait for the data, and the review becomes the excuse for exits that were already priced. The number that settles it is whatever TScan's autoimmune package fetches, and the Pro brief prices the possibilities. 👉 Read Full Analysis
🧬 Cell Therapy
TScan priced the morning after: 75% of the company, and nothing ex vivo survives. TCRX
TScan is cutting approximately 75% of its staff, pausing enrollment in the Phase 3 ALLOHA-2 study of TSC-101 in heme malignancies, and rebuilding around in vivo engineered TCR T therapy for solid tumors, with PRAME and MAGE-A4 candidates entering IND enabling studies and a first IND targeted for Q3 2027, per the company's release. The cuts save $55.0 million through the end of 2027 and stretch the cash into Q4 2027; CEO Gavin MacBeath told Fierce Biotech the Phase 3 pause comes down to insufficient capital, two weeks after Amgen walked away from their $500 million Crohn's collaboration. The line that matters most sits in the middle of the release: the autoimmune program is evaluating strategic partnerships. That makes TScan the first company to formally offer an ex vivo autoimmune cell therapy asset to the market since the Novartis and BMS pauses. Cellares, meanwhile, cut 68 more roles in New Jersey after losing the customer Fierce Pharma identifies as Bristol Myers Squibb, taking its announced reductions to 168. TCRX closed down 42.8%.
💰 Deals
Novartis paid platform rates for the opposite of cell therapy: turning IV biologics into shots. NVS
Novartis took an option and license deal on Alteogen's ALT-B4 (berahyaluronidase alfa), the hyaluronidase that converts intravenous biologics into subcutaneous injections, covering multiple unnamed Novartis products. The headline is up to $3,223 million, but read the construction: Alteogen's release states that total includes option fees, milestones and royalties on net sales, which almost no biobucks headline does, and discloses no upfront at all. Precedent on this exact platform runs small in real money: Biogen paid $20 million upfront against a $549 million total in March, GSK paid $20 million against $265 million in January, and AstraZeneca signed at $1.35 billion in 2025, per Fierce Biotech. Merck has used ALT-B4 for subcutaneous Keytruda since 2020, so Novartis is buying validated, boring delivery certainty in a week when its adventurous modalities made news for the wrong reasons. NVS closed up 0.75% while also telegraphing roughly 130 Swiss job cuts, per Fierce Pharma; no cause assigned.
🧠 Neurology
The first Huntington's gene therapy application is in, and the sponsor closed lower anyway. QURE
uniQure submitted its BLA seeking accelerated approval of AMT-130 (ifezuntirgene inilparvovec) and a parallel UK application, with priority review requested; if granted, that points to a decision around late April or early May 2027, per BioSpace. The evidence is the three year Phase 1/2 dataset against a propensity score matched external control from the Enroll-HD natural history database; the filing release prints no figures, and the 75% slowing of progression comes from the company's September 2025 topline. Remember where this stood ten months ago: the FDA said in November 2025 it no longer agreed the data could support filing, then reversed in June 2026 after the agency's leadership changed, per BioSpace. A filing the FDA talked itself back into is a real asset with a real asterisk, and the market's response captured that: this was a promised third quarter catalyst delivered on schedule, and QURE closed down 3.4%.
🏛️ Policy
The GLP-1 bridge program enrolled 600,000 seniors in two months, by its own count. LLY | NVO
CMS Administrator Mehmet Oz says 600,000 seniors signed up for the Medicare GLP-1 bridge program in its first two months, and the White House says enrollees have saved $216 million; both are government claims and we report them as such. The structure: $50 a month to eligible seniors, $245 net to CMS, covering Zepbound, Foundayo and Wegovy under the Lilly and Novo MFN agreements that took effect July 1. Jefferies' Akash Tewari annualizes the program at $1.5 billion to $1.8 billion, with Lilly taking $900 million to $1.2 billion on roughly 60% share, per Fierce Pharma. KFF puts the eligible pool at 3.8 million. LLY closed flat and NVO rose 3.7%; no cause assigned. Separately, the SEC and FDA signed a three year information sharing MOU, signed by Paul S. Atkins and Kyle Diamantas, giving the SEC streamlined access to non public FDA information for investigations involving public companies. Former SEC enforcement counsel calls it a deliberate signal on biotech insider trading. If your trading window policy predates this week, it is old.
🕳️ The Tally
Wednesday delivered one promised catalyst, and the pattern held on both sides. QURE | TEVA
uniQure's filing was a dated promise on our calendar, delivered inside its Q3 window, and the sponsor closed lower. The running count since Friday is now one sponsor higher out of thirteen delivered catalysts. The other side of the frame also recruited: Teva's anti IL-15 antibody TEV-408 met its Phase 2a primary endpoint in celiac disease, reducing gluten induced intestinal damage versus placebo in a 50 patient gluten challenge study, with zero effect sizes published, per the company's announcement reported by Fierce Biotech. TEVA closed up 3.6%, which makes it the third positive close in our no numbers series, after Jazz and Novartis, and all three were no numbers releases. A Phase 2a carries smaller stakes than the registrational toplines in the series, so log it with that caveat, but the sorting rule keeps sorting: direction pays, magnitude costs. There is no approved celiac drug, and Teva says dose ranging comes before any Phase 3. Friday's edition prints the full week ratio.
📋 Quick Hits
Fortrea acquired Worldwide Clinical Trials' early phase division for $45 million, adding a 200 bed clinical pharmacology unit and a 60,000 square foot bioanalytical lab in Texas, per Fortrea's release; FTRE closed up 3.6%. FTRE
ARPA-H committed $125 million across five teams under its GIVE program to build automated, distributed manufacturing and rapid quality control for personalized RNA based medicines, per the agency's announcement reported by Fierce Pharma.
Biopharma reverse mergers went from one in Q2 to 17 in Q3, per Leerink Partners data reported by BioSpace; the year to date score is 20 IPOs and 19 reverse mergers.
Amylyx logged a fourth straight close below its $35.50 offer price at $34.49, with the $500.2 million offering's closing still unannounced on its release index as of Wednesday evening; the greenshoe forces disclosure by mid September. AMLX
Still no primary document from Novartis on the rap-cel pause, no FDA hold conversion, no Boston Scientific update after September 1, and no Overton hearing date as of Wednesday evening, search only.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The TScan paused versus prioritized table, with the $55.0 million savings math and the 2027 timeline
Every ALT-B4 deal Alteogen has signed, and why this $3.2 billion total reads bigger than it is
The AMT-130 filing table and its full regulatory reversal history
Wednesday's eleven ticker close table, the delivered catalyst log, and a fifteen question FAQ
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 What TScan's strategic partnerships language actually advertises, and the single outcome that will tell you ex vivo autoimmune assets have repriced
💊 Why Alteogen's $3.2 billion is built softer than every other biobucks headline this year, and what Novartis most likely paid in real money
📊 The arithmetic hiding inside the White House's $216 million savings claim, and which obesity giant the bridge program quietly favors
🎯 Plus the coming catalysts, with the full calendar and the week's delivered catalyst tally returning Friday
The halt was Tuesday's news; the repricing was Wednesday's. TScan put the first ex vivo autoimmune asset on the shelf, and what it fetches will outlive everything else in this issue. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →